N/A N=5 Impact of Structured Physical Activity Education Delivery in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Mean Change in Hemoglobin A1c (HbA1c) Levels — 0.001; -0.007 mmol/mol
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 Diabetes Prevention and Control in the Workplace: A Pilot Study
Type 2 Diabetes Mellitus
Primary: Body Weight — -2.3; 0.73 kg — p=<0.01
Phase 3 N=59 Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
Primary Immune Deficiency Disorder
Primary: Number of Serious Bacterial Infections (SBIs) Per Subject Per Year (FDA Guidance for Industry (2008)) — 0 SBIs/subject/year
N/A N=30 Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds
Lid-Parallel Conjunctival Folds
Primary: Lid-Parallel Conjunctival Folds (LIPCOF) — 1.95; 1.75; 1.70; 1.40 Score
Phase 4 N=23,687 Continuous Chest Compressions vs AHA Standard CPR of 30:2
Out of Hospital Cardiac Arrest
Primary: Number of Participants Who Survive From the Time of Cardiac Arrest to Hospital Discharge — 1072; 1127 participants
Phase 3 N=54 Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature
Growth Disorder · Idiopathic Short Stature
Primary: Height Velocity (Ht-V) — 12.02; 6.87 cm/year — p=<0.0001
Phase 4 N=6,208 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old
Asthma
Primary: Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal…
Phase 2 N=101 A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.92; 0.95 AECOPD events/person-year — p=0.941
N/A N=209 Repeated Insult Patch Test of Personal Lubricants
Erythema · Edema
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0 participants
Phase 4 N=111 Treatment of Peripheral T-cell Lymphoma
Peripheral T-cell Lymphoma
Primary: Progression-free Survival — 35; 27 participants
Phase 2 N=23 FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Safety of Low-dose FK-506 in PAH — 8; 18; 9; 22 number of AEs
N/A N=20 Effects of Multifocal Contact Lens on Ocular Tissue
Visual Acuity
Primary: Upper Eye Lid Margin Staining — 1.96 mm^2
N/A N=151 SMS Turkey: Harnessing the Power of Text Messaging to Promote Smoking Cessation
Smoking
Primary: Carbon Monoxide-verified Continuous Abstinence at 12 Weeks — 8; 4 participants
Phase 2 N=34 Assessment of a Syringe Pump to Pre-eclamptic Women in a Low-resource Hospital
Pre-eclampsia
Primary: Error in the Total Volume Dispensed and Flow Rate — NA; -1.48; NA; -1.75 percentage of error
Phase 1 N=42 Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
Melanoma
Primary: Number of Participants Experiencing Adverse Events (AEs) — 34; 8 Participants